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1. Introduction
  Pregnancy-induced hypertension (PIH) is common 
in patients with 20-week pregnancy and of 2-week 
postpartum. If the blood pressure can not be effectively 
controlled, it will be a serious threat to the health of 
maternal and newborn[1]. Although the cause is still not 
clear, the main pathological changes are the diastole of 
vessel and erosion defects of trophoblast. In recent years, 
magnesium sulfate and nifudipine is the main therapy, 
which not only has anticonvulsant effect, but also can change 
the level of the soluble vascular cell adhesion molecule 1 
(sVCAM-1) and high-sensitivity C-reactive protein (hs-
CRP) of patients with PIH. But the reports about N-terminal 
pro-brain natriuretic peptide (NT-proBNP) are few. In 
this study, we studied the effect of magnesium sulfate and 
nifudipine on expression hs-CRP, sVCAM-1, NT-proBNP 
in plasma and investigate the therapeutical mechanism of 
PIH to provide evidence for the clinical practice.
Objective: To investigate the change of the hs-CRP, sVCAM-1, NT-proBNP levels of the patients 
with pregnancy-induced hypertension (PIH) syndrome. Methods: A total of 200 patients with PIH 
were divided into mild, moderate and severe group, and 50 healthy pregnancy patients served as 
the control group. The serum sVCAM-1 levels were detected by enzyme-linked immunosorbent 
assay, hs-CRP were detected by immunity transmission turbidity, and NT-proBNP levels were 
determined by the colloidal gold method. Patients were treated with magnesium sulfate and 
nifudipine and the contrastive analysis was performed before and after treatment. And the 
pathological changes in placental of PIH patients were detected by hematoxylin-eosin staining 
at the same time. Results: The hs-CRP, sVCAM-1, NT-proBNP levels of patients in the mild, 
moderate and severe PIH group were significantly higher than that in the control group (P<0.05). 
The hs-CRP, sVCAM-1, NT-proBNP levels in the severe group were significantly higher than the 
mild group and the moderate group, the difference was statistically significant (P<0.05). The hs-
CRP, sVCAM-1, NT-proBNP of the moderate group were significantly higher than the mild group 
(P<0.05). There was a positive correlation between hs-CRP, sVCAM-1, NT-proBNP expression 
levels and the degree of the PIH. The expression of hs-CRP, sVCAM-1, NT-proBNP levels of the 
moderate and the severe group were significantly decreased (P<0.05). The number of placental 
villi and interstitial blood vessel in the moderate and severe PIH group were significantly less 
than the control group (P<0.05). Conclusions: The increased levels of serum hs-CRP, sVCAM-1, 
NT-proBNP may be involved in the process of vascular endothelial cell injury of the PIH, and 
the hs-CRP, sVCAM-1, NT-proBNP can be used as the auxiliary index for diagnosis of PIH and 
determination of PIH severity.
Li Wang et al./Asian Pacific Journal of Tropical Medicine (2013)897-901898
2. Materials and methods
2.1. General information 
   A total of 200 cases diagnosed as PIH from March 2009 
to March 2012 in our hospital were enrolled. The patients 
were 22-33 years old, (28.5暲9.6) years old on average. The 
average systolic pressure was (155.8暲15.7) mmHg, and the 
average diastolic pressure was (91.5暲6.5) mmHg. They were 
divided into mild, moderate and severe PIH group according 
to the “Obstetrics and Gynecology” standards. The inclusion 
criteria were as following: primipara; complete information; 
pregnant in our hospital. Exclusion criteria were as 
following: previous history of hypertension, diabetes, chronic 
kidney disease or cardiovascular disease; other pregnancy 
complications. A total of 50 cases were selected as normal 
control group at the same time, and there was proportionality 
in the age, gestational age and history between both groups 
(P>0.05).
 
2.2. Treatment
  Routine examination such as blood and urine test, liver 
and kidney function, ECG, fundus examination, etc. were 
performed. Sixty mL 25% magnesium sulfate was added to 
500 mL 5% glucose solution, then was injected into patients 
by intravenous drip, and the nifedipine controlled release 
tablet was given orally 30 mg/time, 1 time/d. For patients 
with the gestational age <37 weeks, drugs to promote lung 
ripe were also given.
2.3. Test and collection of specimen
2.3.1. Plasma specimens
  Four mL of fasting venous blood were obtained from 
patients before and after 24 h of the treatment. Samples were 
immediately placed in 60 uL tube, then was mixed with 
100 g/L edetate disodium, centrifuged at 4 曟. The serum 
was obtained and then prepared at the -80 曟 refrigerator. 
The serum sVCAM-1 concentrations were detected by 
enzyme-linked immunosorbent assay, the serum hs-CRP 
concentrations were detected by rate turbidimetric method, 
and the NT-proBNP concentration were detected by the 
colloidal gold stripes. hs-CRP, sVCAM-1, NT-proBNP kits 
were from Boehringer Mannheim company, and all measure 
operation steps were strictly followed.
2.3.2. Tissue samples 
  A 1 cm 暳 1 cm 暳1 cm size tissue was obtained from the 
maternal side of the placenta and then placed in 10% neutral 
formalin for 24 h, embedded in paraffin, sliced and then 
was stained by HE staining. The histological changes of the 
placenta were observed. The 10 non-overlapping (暳200) 
field was selected, the number of blood vessels of villous 
stroma and of villi was read, then the average value was 
calculated, respectively.
2.4. Statistical analysisx
  The data was analyzed with SPSS13.0 software. Since 
the hs-CRP, sVCAM-1, NT-proBNP were not normally 
distributed, we applied Wilcoxon non-parametric test 
for statistical analysis. Correlation was analyzed with the 
Speraman correlation analysis, P<0.05 was regarded as 
statistical significance.
 
  
3. Results
3.1. Comparison of hs-CRP, sVCAM-1, NT-proBNP of 
patients with mild, moderate and severe PIH
  hs-CRP, sVCAM-1, NT-proBNP levels of patients in the 
observation group were significantly higher than the control 
group (P<0.05), and were increased with the aggravation 
of PIH. The hs-CRP, sVCAM-1, NT-proBNP levels in the 
moderate group were significantly higher than in the mild 
group (P<0.05). The hs-CRP, sVCAM-1, NT-proBNP levels 
in the severe group were significantly higher than in the 
mild group and the moderate group (P<0.05) (Table 1).
3.2. Correlation between hs-CRP, sVCAM-1, NT-proBNP 
and the severity of PIH
  There was a positive correlation between the hs-CRP, 
sVCAM-1, NT-proBNP expression levels and the degree 
of PIH, the correlation coefficients were r=0.569, P<0.05; 
r=0.489, P<0.05; r=0.592, P<0.05, respectively.
3.3. Change of hs-CRP, sVCAM-1, NT-proBNP expression 
levels after treatment in mild, moderate and severe PIH group
  After the therapy with magnesium sulfate and nifudipine, 
the systolic blood pressure and diastolic blood pressure were 
significantly reduced, the average systolic blood pressure 
was (133.2暲8.3) mmHg, and the average diastolic blood 
pressure was (82.1暲5.2) mmHg. The hs-CRP, sVCAM-1, NT-
proBNP levels were significantly decreased after treatment 
in the moderate group and the severe group (P <0.05). There 
was no significantly different of the hs-CRP, sVCAM-1 and 
NT-proBNP level before and after treatment for patients in 
the mild group (P>0.05) (Table 2).
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3.4. Pathological result
  The number of placental villi and the interstitial blood 
vessel reduced with the severity of PIH, and the number in 
the moderate and severe group was significantly less than 
the control group and the mild group (P<0.05). The number of 
the placental villi and the interstitial blood vessel between 
the mild PIH group and the normal control group had no 
significant difference (P>0.05). The number of the placental 
villi and the interstitial blood vessel between the moderate 
group and the severe group had no significant difference (P> 
0.05) (Table 3).
Table 3 
Pathological changes of different levels PIH.
Groups n Number of placental 
villi
Number of interstitial 
blood vessel
Control group 50 15.5暲1.8 41.2暲3.4
Mild group 62 13.8暲1.7 36.8暲3.1
Moderate group 57 11.3暲1.4*吟 25.9暲2.4*吟
Severe group 81 10.5暲1.3*吟 22.8暲2.0*吟
Note: *Compared with control group P<0. 05; 吟compared with the 
mild group P<0. 05.
4. Discussion
  PIH is a common obstetric disorders, accounting for 5% 
-10% of pregnancy[2-5]. It often occurred at 20 weeks of 
gestation and two weeks postpartum. The maternal mortality 
rate accounted for 10%-16% of pregnancy-related deaths, 
which is a high risk factor for maternal mortality. Patients 
are often associated with hypertension, proteinuria, edema, 
convulsions, coma, heart and kidney failure, etc. And other 
complications may also occur to patients such as pulmonary 
edema, acute heart failure, acute renal insufficiency 
herniation, cerebrovascular accident, aspiration pneumonia, 
placental abruption, fetal distress, fetal death etc. Timely 
and effective treatment must be taken to save the lives of 
pregnant women. It must be considered more during the 
course of treatment of PIH,not only to achieve the purpose 
of treatment of disease, but also to ensure that maternal and 
child health, and avoid adverse effects on the mother and 
child of the therapeutic interventions[6-8].
  We use HE staining to observe the pathological changes 
of the placenta of patients with PIH. The number of the 
placental villi and the interstitial blood vessel reduced with 
the severity of PIH, and the number in the moderate and 
severe group was significantly less than the control group 
and the mild group, which suggested that there will be 
varying degrees of damage to the body if the blood pressure 
keep raising without timely control, and there may be life-
threatening in severe cases. In this study, we adopted 
the therapy with magnesium sulfate and nifudipine as a 
treatment of PIH, which had a good effect. The hs-CRP, 
sVCAM-1, NT-proBNP levels in serum before and after 
treatment were detected by ELISA to predict the changes in 
disease.
  hs-CRP are stress proteins synthesized by the liver and 
released into the blood, compared with CRP levels, it is 
more sensitive and more easily to be detected as stimulated. 
In this study, the experimental results show that the hs-CRP 
levels in the PIH group were significantly higher than in 
Table 1 
hs-CRP, sVCAM-1, NT-proBNP expression levels of different patients. 
Groups n sVCAM-1 (mg/mL) hs-CRP (mg/L) NT-proBNP (ng/L)
Control group   50     664.1暲172.3   2.6暲1.2   62.0暲12.0
Observation group 200   1 585.5暲786.2* 42.7暲7.8* 183.5暲26.5*
Mild group   62      882.7暲201.9*   8.3暲2.1*   93.1暲16.2*
Moderate group   57   1 654.8暲652.6*吟 32.1暲7.3*吟 175.0暲23.2*吟
Severe group   81 19 874.6暲931.5*吟書 56.5暲12.7*吟書 263.5暲32.0*吟書
Note: * Compared with control group P<0.05; 吟compared with the mild group P<0.05; 書compared with the moderate group P<0.05.
Table 2 
Changes of hs-CRP, sVCAM-1, NT-proBNP before and after treatment in patients with varying degrees of PIH.
Groups n sVCAM-1 (mg/mL) hs-CRP( mg/L) NT-proBNP( ng/L)
Before treatment After treatment Before treatment After treatment Before treatment After treatment
Mild 62     882.7暲201.9    798.2暲152.8   8.3暲2.1   7.5暲1.2   93.1暲16.2   83.7暲10.2
Moderate 57  1 654.8暲652.6 1 306.2暲492.9* 32.1暲7.3 16.9暲4.7* 175.0暲23.2   97.3暲15.4*
Severe 81 19 874.6暲931.5 1 282.6暲622.6* 56.5暲12.7 21.3暲6.2* 263.5暲32.0 105.3暲 20.4*
Note: * compared with the level before treatment, P<0.05.
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normal pregnancy group, and increased with the aggravation 
of PIH. There is a positive correlation between the hs-CRP 
and the degree of PIH. hs-CRP is a marker of inflammation 
with high sensitivity and accuracy, which is closely related 
to tissue damage. The level of hs-CRP directly reflects the 
degree of inflammatory response, often as a reliable basis for 
the tissue damage[9-13]. After the therapy with magnesium 
sulfate and nifudipine, the blood pressure is significantly 
lower of patients with PIH. And the hs-CRP levels were 
significantly decreased of patients with PIH in the moderate 
and severe group, the difference was statistically significant. 
PIH is a special kind of inflammatory reactions. When the 
condition became more serious, the liver cells synthesized 
and secreted a large number of hs-CRP and released into the 
blood circulation because of the stimulation, and resulting 
in elevated concentration in the peripheral blood[15-18]. 
Therefore, hs-CRP can be used as the monitoring indicators 
of PIH.
  sVCAM-1 belongs to the immunoglobulin superfamily 
which is soluble. It can binding with the T cells, NK cells 
and monocytes VLA-4 and mediated adhesion and migration 
of those cells, it also involved in inflammatory and immune 
processes[19]. The damage of hypoxia and oxidative can 
enhanced the expression of endothelial cell sVCAM-1, 
while the increase of endothelial cells SVCAM-1 can lead to 
the imbalance of vascular endothelial cell function. In this 
study, we compared the level of sVCAM-1 in mild, moderate 
and severe PIH group and found low sVCAM-1 expression in 
patients with mild PIH group, and the expression gradually 
increased in moderate and severe PIH group. The more 
severe the disease is, the higher the sVCAM-1 expression is.
  In this study, we think that the serum sVCAM-1 expression 
levels increasing with the severity of the disease, it reflect 
the sVCAM-1 synthesis is also increasing in vivo of patients 
with PIH, which suggested that sVCAM-1 possibly involved 
in the development of PIH by damaging the vascular 
endothelial cells. After the therapy with magnesium sulfate 
and nifudipine, the sVCAM-1 expression in the moderate 
and severe group was significantly reduced. The treatment 
may reducing the blood vessel injury by controlling the 
patient’s blood pressure, which suggested the therapy with 
magnesium sulfate and nifudipine to PIH had a good clinical 
effect.
  Brain natriuretic peptide (brain natriurefic peptide, 
BNP) mainly synthesize and secreted by the ventricular 
muscle cells, which were expressed both in the ventricles 
and brain tissue. It had functions such as expand the 
arteriovenous, inhibit sympathetic activity and antagonize 
the renin-angiotensin-aldosterone system and some other 
effects[20]. The plasma BNP expression levels did not change 
significantly at different stages of PIH, so it can not be 
used to determine the severity of PIH. NT-proBNP is the 
BNP precursor cleaved into the BNP N-terminal fragment. 
Studies have confirmed that NT-proBNP was with longer 
half-life and higher serum concentrations, and it is more 
easily to be detected[21-24]. It can be used as an indicator to 
assess the cardiac function of patients with PIH. The study 
of Chen[25] suggest that NT-proBNP had the high expression 
in PIH, so the NT-proBNP test can help to determine the 
severity of PIH. Our experimental results showed that the 
NT-proBNP are kept in a low and stable level in the normal 
control group, but the NT-proBNP levels in the patient 
group were significantly higher than in the control group. 
And the NT-proBNP expression level gradually increased 
with the aggravation of PIH. And the NT-proBNP level in the 
severe group was higher than that in the mild group and the 
moderate group, which suggested that the heart of healthy 
pregnant women can adapt to the increased load capacity 
during pregnancy, while the heart of PIH patient may have 
some disorder to adjust the change of heart volume load.
  In summary, the hs-CRP, sVCAM-1 and NT-proBNP levels 
in the PIH group were significantly higher and increased 
with the aggravation of PIH, which suggested the hs-CRP, 
sVCAM-1, NT-proBNP levels can help to monitor the 
development of PIH. Early detection and early treatment can 
ensure the health of mother and child.
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